Pneumogenesis” has been created, to serve patients and provide innovative treatments to otherwise incurable respiratory diseases. Its main objective is to promote the therapeutic potential of stem cells through innovative research in the field of regenerative medicine, with the elaboration of cutting-edge clinical protocols and expert medical consulting. Our mission is to unravel the potential of using adipose-derived adult stem cells for autologous transplantation, in an effort to combat incurable lung diseases. Our corporate group has conducted the first worldwide prospective, randomized clinical trial (Phase IB) on the use of adipose-derived stem cells for the treatment of Idiopathic Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis (IPF) is a devastating pulmonary disease of unknown etiology with dismal prognosis and an estimated life span ranging from 3-5 years irrespective of treatment. The pathogenic mechanisms leading to progressive lung scarring and ultimately respiratory failure, remain largely unclear. Up-to-date, all conventional treatments with corticosteroids, anti-oxidants, immunosuppressive and anti-fibrotic drugs have been unsuccessful, and the only effective approach for patients with IPF is lung transplantation.